Kaken Pharmaceutical Co Ltd 2021 IR
The report outlines Kaken Pharmaceutical's value creation process, medium-term business plan, and ESG initiatives for fiscal year 2020. Key highlights include the launch of Ecclock, Japan's first topical treatment for primary axillary hyperhidrosis, and the expansion of onychomycosis treatment Clenafin in global markets. On the environmental front, the company reduced its carbon dioxide emissions to 20,605 tonnes and electricity consumption to 25,038 thousand kilowatt-hours. Additionally, the company achieved an employment rate of 3.22% for individuals with disabilities and promoted work-life balance through a flextime system.
Company: Kaken Pharmaceutical Co Ltd
Sector: Health Care
Country: Japan
Year: 2021
Type: IR
Pages: 37
Kaken Pharmaceutical Co Ltd
Corporate Report
The report outlines Kaken Pharmaceutical's value creation process, medium-term business plan, and ESG initiatives for fiscal year 2020. Key highlights include the launch of Ecclock, Japan's first topical treatment for primary axillary hyperhidrosis, and the expansion of onychomycosis treatment Clenafin in global markets. On the environmental front, the company reduced its carbon dioxide emissions to 20,605 tonnes and electricity consumption to 25,038 thousand kilowatt-hours. Additionally, the company achieved an employment rate of 3.22% for individuals with disabilities and promoted work-life balance through a flextime system.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Apr 1, 2020 - Mar 31, 2021
Fiscal Year
2020
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Water Consumption
Total Waste
Employees